PRINCETON, N.J.--(BUSINESS WIRE)--NJ Bio, Inc. and Charles River Laboratories, Inc. have announced a strategic alliance to offer complementary services to clients including early development and optimization to manufacturing of antibody drug conjugates (ADCs).
It is well known that the path of bringing ADCs to market is an intricate and complex field that requires expert navigation skills. It involves development and manufacturing processes of antibodies (Abs), cytotoxic payloads, linkers, linker-payloads, their conjugation to ADCs, and preclinical and clinical validations. The biggest benefit of the Charles River and NJ Bio alliance is that clients can receive seamless complementary services to enhance outcomes and accelerate time-to-market for their ADCs. Today, innovation has become a necessity to improve the safety and efficacy profiles of ADCs. Another advantage of this alliance to clients is Charles River’s ability to discover innovative engineered Abs while NJ Bio will synthesize and manufacture novel linkers, payloads, or linker-payloads to enhance the safety and efficacy of ADCs.
Charles River is a leader in antibody development and preclinical evaluation of ADCs. The Company’s antibody, oncology, immunology and safety assessment experts can support ADC programs from proof-of-concept to clinical candidates, helping drive translational success and accelerating the path to the clinic. Last year, in recognition of Charles River’s leadership in ADC discovery and development, the Company was awarded the Best Contract Research Organization at the World ADC Summit, and is shortlisted for the award again this year.
NJ Bio, Inc., is a contract research organization located in Princeton, NJ specializing in providing integrated chemistry and bioconjugation services. Committed to innovation and quality, NJ Bio assists its clients in achieving their development and manufacturing objectives. NJ Bio has significant expertise in the synthesis and GMP manufacturing of payloads, linkers, linker-payloads, ADCs, TPDs, and oligo-conjugates, and non-oncology related conjugations. NJ Bio has an excellent track record with clients to support early phase discovery, proof-of-concept, process and analytical development, manufacture of pre-clinical batches, and manufacture and release of linkers, payloads, linker-payloads, and ADCs in GMP facility. A testament to NJ Bio’s valued offerings to its clients is being recognized as “Best Contract Research Organization (CRO)” for three consecutive years at the World ADC Summit and it is a contender for a fourth award this November.
About Charles River Laboratories
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
About NJ Bio, Inc.
NJ Bio, Inc. is a leading Contract Research Organization (CRO)/ Contract Development and Manufacturing Organization (CDMO) headquartered in Princeton, NJ, with additional chemistry facilities in Bristol, PA and Mumbai, India, providing integrated chemistry and biology services to companies in the biotech and pharmaceutical sectors. The NJ Bio team has robust expertise in bioconjugation, synthetic organic chemistry, protein-based biopharmaceuticals, and GMP manufacturing that enables clients to receive customized ADC solutions that could speed up their discovery and development. To learn more about our services, visit www.njbio.com.
For more information, please visit www.njbio.com or www.criver.com.
